Daxor (NASDAQ:DXR) specializes in medical instrumentation and biotechnology, focusing on innovative blood volume analysis. This unique approach provides critical information that benefits patient care in heart failure, critical care, and surgery, alongside supporting medical research. Daxor aims to revolutionize how doctors diagnose and treat heart and lung diseases by offering precise, personalized patient insights. The company's flagship product, the BVA-100 blood volume analyzer, stands at the forefront of their technology, enabling accurate measurement of blood volume and composition. Daxor's objective is to improve outcomes and reduce healthcare costs through the adoption of their blood volume analysis technology in clinical practices worldwide.